Clinical trial
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus…
NCT00391053 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00391053 |
|---|---|
| Title | Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly |
| Official title | Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age. |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Orthomyxoviridae Infection, Influenza, Myxovirus Infection |
| Intervention type | Biological |
| Interventions | High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated |
| Enrollment | 3,851 |
| Start date | Oct 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Oct 23, 2006 |
| Last update posted | Apr 14, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: